The FDA Adverse Event Reporting System (FAERS) was used to evaluate the associations between oral anticoagulants (OACs) and acute kidney injury (AKI). Disproportionality analysis were applied to data
Top 20 least sparse features. The top 20 least sparse multi-variate features per dataset and patient group (i.e., ADE positive and ADE negative patients). The feature names are encoded as Nomenclature